YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Chemomab Therapeutics Ltd. TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases wit…
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and sig…
(RTTNews) - Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tecto…
(RTTNews) - Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the…
─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Approval for the T…
(RTTNews) - A quiet news day didn't stop several high-volatility healthcare and cannabis stocks from posting sharp after-hours gains on Friday, with traders leaning into recent catalysts and technical momentum. Tilray Brands, Inc. (TLRY):…
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macroph…
Alkermes plc ALKS announced that it has entered into a definitive agreement to acquire Ireland-based Avadel Pharmaceuticals AVDL in a deal valued at up to $20.00 per share in cash, representing a total transaction value of approximately $2…
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Oct. 23: Par Pacific Holdings, Inc. PARR: This energy and infrastructure business has a Zacks Rank #1 and witnessed the Zacks Consensu…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Marqeta, Inc. MQ: This card issuing platform has seen the Zacks Consensus Estimate for its current year earnings increasing 42.9% over the last 60 days. Marqeta, Inc.…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
Sanofi SNY announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary and key secondary endpoints. An inherite…
Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are receiving standard therapy. The approval als…
Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults with type II diabetes (T2D). This appro…
Esperion Therapeutics ESPR announced that it has nominated ESP-2001, a highly specific allosteric ATP citrate lyase (“ACLY”) inhibitor, as its new preclinical development candidate for the treatment of primary sclerosing cholangitis (“PSC”…
Novo Nordisk NVO shares fell roughly 4% in pre-market trading today after U.S. President Donald Trump signaled potential steep price cuts for the company’s blockbuster GLP-1 RA drugs during a White House event on Thursday. NVO markets sema…
Viatris VTRS announced the acquisition of Tokyo-based Aculys Pharma, a clinical-stage biopharmaceutical company specializing in neurological therapies. The deal grants Viatris the rights to develop and commercialize pitolisant and Spydia (…
Corcept Therapeutics CORT announced that it has submitted a marketing authorization application (MAA) seeking approval for its lead pipeline candidate, relacorilant, to treat patients with platinum-resistant ovarian cancer to the European…
Rocket Pharmaceuticals RCKT announced that the FDA has accepted the resubmitted biologics license application (BLA) seeking approval for its gene therapy Kresladi (marnetegragene autotemcel; marne-cel) to treat patients with severe leukocy…
Shares of Tvardi Therapeutics TVRD nosedived 83.9% on Monday after the company provided a disappointing update following an analysis of preliminary data from a mid-stage study of its lead investigational candidate, TTI-101, to treat idiopa…
Zoetis ZTS announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, Lenivia (izenivetmab). The recommendation…
Teva Pharmaceutical Industries Limited TEVA recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone). The regulatory body has now approved Uzedy (50 mg, 75 mg and 100 mg) as a once-monthly exten…
Cidara Therapeutics CDTX announced that the FDA has granted a Breakthrough Therapy designation to its lead pipeline candidate, CD388, for the prevention of seasonal influenza. Shares of the company were up 12.4% following the announcement…
Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage study of the company’s lead investigational candidate, OV329. The candidate is a next-generation GABA-AT inhibitor…
Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of persistent corneal epithelial defect (PCED)…
AstraZeneca AZN announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with resistant hypertension. Patients with treatment…
Merck MRK announced that it has initiated three separate phase IIb studies evaluating its investigational TL1A inhibitor, tulisokibart (MK-7240), in three new immune-mediated inflammatory diseases. The three new phase IIb studies will eval…
SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substant…
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamental…
New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential o…
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks…
─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Resultsin Primary Sclerosing Cholangitis (PSC)─ ─AchievedAlignmentwith FDA on Clear and Efficient Pathwayto Potential Regulatory Approval fo…
Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies o…
—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis— —Chemomab's CCL24-Neutralizing Antibody CM-101 Is Expected to Enter a Phase 2 Trial in Sy…
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares climbed 356.8% to close at $45.50 on Thursday following an announcement the company will merge with Trump Media & Technology Group. Portillo's Inc. (NASDAQ: PTLO) rose 45.5% to…
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 132.3% to $23.14 following an announcement the company will merge with Trump Media & Technology Group. Portillo's Inc. (NASDAQ: PTLO) gained 45.9% to $29.18 after the com…